NAFLD risk alleles in PNPLA3, TM6SF2, GCKR, and LYPLAL1 show divergent metabolic effects

In this study, Nightingale’s blood biomarker analysis service was used to quantify metabolic measures (including detailed lipid and lipoprotein particle profiles), for 1,810 individuals (N fatty liver =338) from The Cardiovascular Risk in Young Finns Study.

This study illustrates how combining genetic and metabolic profiling could enhance better classification and targeted treatment of NAFLD subtypes.